162 related articles for article (PubMed ID: 32821277)
1. Evolution of tumor cells during AsiDNA treatment results in energy exhaustion, decrease in responsiveness to signal, and higher sensitivity to the drug.
Girard PM; Berthault N; Kozlac M; Ferreira S; Jdey W; Bhaskara S; Alekseev S; Thomas F; Dutreix M
Evol Appl; 2020 Aug; 13(7):1673-1680. PubMed ID: 32821277
[TBL] [Abstract][Full Text] [Related]
2. AsiDNA Treatment Induces Cumulative Antitumor Efficacy with a Low Probability of Acquired Resistance.
Jdey W; Kozlak M; Alekseev S; Thierry S; Lascaux P; Girard PM; Bono F; Dutreix M
Neoplasia; 2019 Sep; 21(9):863-871. PubMed ID: 31362243
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Studies Comparing Efficacy and Toxicity of DNA Repair Inhibitors, Olaparib, and AsiDNA, in the Treatment of Carboplatin-Resistant Tumors.
Herath NI; Berthault N; Thierry S; Jdey W; Lienafa MC; Bono F; Noguiez-Hellin P; Sun JS; Dutreix M
Front Oncol; 2019; 9():1097. PubMed ID: 31781480
[No Abstract] [Full Text] [Related]
4. Inhibition of DNA Repair by Inappropriate Activation of ATM, PARP, and DNA-PK with the Drug Agonist AsiDNA.
Berthault N; Bergam P; Pereira F; Girard PM; Dutreix M
Cells; 2022 Jul; 11(14):. PubMed ID: 35883597
[TBL] [Abstract][Full Text] [Related]
5. Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.
Jdey W; Thierry S; Russo C; Devun F; Al Abo M; Noguiez-Hellin P; Sun JS; Barillot E; Zinovyev A; Kuperstein I; Pommier Y; Dutreix M
Clin Cancer Res; 2017 Feb; 23(4):1001-1011. PubMed ID: 27559053
[No Abstract] [Full Text] [Related]
6. The DNA Repair Inhibitor Dbait Is Specific for Malignant Hematologic Cells in Blood.
Thierry S; Jdey W; Alculumbre S; Soumelis V; Noguiez-Hellin P; Dutreix M
Mol Cancer Ther; 2017 Dec; 16(12):2817-2827. PubMed ID: 28947503
[TBL] [Abstract][Full Text] [Related]
7. Effect of DNA repair inhibitor AsiDNA on the incidence of telomere fusion in crisis.
Subecz C; Sun JS; Roger L
Hum Mol Genet; 2021 Apr; 30(3-4):172-181. PubMed ID: 33480989
[TBL] [Abstract][Full Text] [Related]
8. Micronuclei Frequency in Tumors Is a Predictive Biomarker for Genetic Instability and Sensitivity to the DNA Repair Inhibitor AsiDNA.
Jdey W; Thierry S; Popova T; Stern MH; Dutreix M
Cancer Res; 2017 Aug; 77(16):4207-4216. PubMed ID: 28588010
[TBL] [Abstract][Full Text] [Related]
9. AsiDNA Is a Radiosensitizer with no Added Toxicity in Medulloblastoma Pediatric Models.
Ferreira S; Foray C; Gatto A; Larcher M; Heinrich S; Lupu M; Mispelter J; Boussin FD; Pouponnot C; Dutreix M
Clin Cancer Res; 2020 Nov; 26(21):5735-5746. PubMed ID: 32900798
[TBL] [Abstract][Full Text] [Related]
10. A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours.
Le Tourneau C; Delord JP; Kotecki N; Borcoman E; Gomez-Roca C; Hescot S; Jungels C; Vincent-Salomon A; Cockenpot V; Eberst L; Molé A; Jdey W; Bono F; Trochon-Joseph V; Toussaint H; Zandanel C; Adamiec O; de Beaumont O; Cassier PA
Br J Cancer; 2020 Nov; 123(10):1481-1489. PubMed ID: 32839491
[TBL] [Abstract][Full Text] [Related]
11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
12. Combination DNA Damage Response (DDR) Inhibitors to Overcome Drug Resistance in Ovarian Cancer.
Nasioudis D; George EM; Xu H; Kim H; Simpkins F
Cancer Treat Res; 2023; 186():189-206. PubMed ID: 37978137
[TBL] [Abstract][Full Text] [Related]
13. Planning Implications Related to Sterilization-Sensitive Science Investigations Associated with Mars Sample Return (MSR).
Velbel MA; Cockell CS; Glavin DP; Marty B; Regberg AB; Smith AL; Tosca NJ; Wadhwa M; Kminek G; Meyer MA; Beaty DW; Carrier BL; Haltigin T; Hays LE; Agee CB; Busemann H; Cavalazzi B; Debaille V; Grady MM; Hauber E; Hutzler A; McCubbin FM; Pratt LM; Smith CL; Summons RE; Swindle TD; Tait KT; Udry A; Usui T; Westall F; Zorzano MP
Astrobiology; 2022 Jun; 22(S1):S112-S164. PubMed ID: 34904892
[TBL] [Abstract][Full Text] [Related]
14. Neoplastic growth: the consequence of evolutionary malignant resistance to chronic damage for survival of cells (review of a new theory of the origin of cancer).
Monceviciūte-Eringiene E
Med Hypotheses; 2005; 65(3):595-604. PubMed ID: 15919162
[TBL] [Abstract][Full Text] [Related]
15. Molecular targeted drugs resistance impairs double-strand break repair and sensitizes ER-positive breast cancer to PARP inhibitors.
Suzuki Y; Wenwen W; Ohta T; Hayashi SI
Breast Cancer; 2022 Jan; 29(1):77-91. PubMed ID: 34346034
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in
Färkkilä A; Rodríguez A; Oikkonen J; Gulhan DC; Nguyen H; Domínguez J; Ramos S; Mills CE; Pérez-Villatoro F; Lazaro JB; Zhou J; Clairmont CS; Moreau LA; Park PJ; Sorger PK; Hautaniemi S; Frias S; D'Andrea AD
Cancer Res; 2021 May; 81(10):2774-2787. PubMed ID: 33514515
[TBL] [Abstract][Full Text] [Related]
17. The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways.
Mini E; Landini I; Lucarini L; Lapucci A; Napoli C; Perrone G; Tassi R; Masini E; Moroni F; Nobili S
Oncol Res; 2017 Nov; 25(9):1441-1451. PubMed ID: 28429680
[TBL] [Abstract][Full Text] [Related]
18. Diversification and enrichment of clinical biomaterials inspired by Darwinian evolution.
Green DW; Watson GS; Watson JA; Lee DJ; Lee JM; Jung HS
Acta Biomater; 2016 Sep; 42():33-45. PubMed ID: 27381524
[TBL] [Abstract][Full Text] [Related]
19. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
Lau CH; Seow KM; Chen KH
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
[TBL] [Abstract][Full Text] [Related]
20. Protein promiscuity: drug resistance and native functions--HIV-1 case.
Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
